Aarti Drugs Ltd. logo

Aarti Drugs Ltd. (AARTIDRUGS)

Market Closed
10 Aug, 10:00
XNSE XNSE
422. 55
+6.35
+1.5257%
41.5B Market Cap
- P/E Ratio
4% Div Yield
216,655 Volume
- Eps
416.2
Previous Close
Add Transaction
Day Range
413.4 424.4
Year Range
318.95 534.55
Want to track AARTIDRUGS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AARTIDRUGS closed today higher at ₹422.55, an increase of 1.5257% from yesterday's close, completing a monthly increase of 11.9338% or ₹45.05. Over the past 12 months, AARTIDRUGS stock gained 2.4239%.
AARTIDRUGS pays dividends to its shareholders, with the most recent payment made on Mar 04, 2026. The next estimated payment will be in In 6 months on Mar 04, 2027 for a total of ₹2.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0167%, based on the last three reports.
Aarti Drugs Ltd. has completed 2 stock splits, with the recent split occurring on Sep 30, 2020.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

AARTIDRUGS Chart

People also search for

Wockhardt Ltd.
1,931.2
-4.4433%
Piramal Pharma Ltd.
213.61
+1.9375%
CIE Automotive India Ltd.
409.5
-0.2436%
Ola Electric Mobility Ltd.
39.3
-4.3097%
Natco Pharma Ltd.
910.5
-0.6709%

Aarti Drugs Ltd. (AARTIDRUGS) FAQ

What is the stock price today?

The current price is ₹422.55.

On which exchange is it traded?

Aarti Drugs Ltd. is listed on XNSE.

What is its stock symbol?

The ticker symbol is AARTIDRUGS.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4%.

What is its market cap?

As of today, the market cap is 41.5B.

Has Aarti Drugs Ltd. ever had a stock split?

Aarti Drugs Ltd. had 2 splits and the recent split was on Sep 30, 2020.

Aarti Drugs Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Prakash Moreshwar Patil CEO
XNSE Exchange
Y0000M112 CUSIP
India Country
1,064 Employees
9 Feb 2026 Last Dividend
24 Mar 2015 Last Split
- IPO Date

Overview

Aarti Drugs Limited, established in 1984, is a comprehensive pharmaceutical company with global operations, focusing on the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations. With a strong presence in various therapeutic areas, the company caters to a wide spectrum of healthcare needs. It operates both in India and internationally, demonstrating a robust portfolio that spans across various medical disciplines, such as anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, and more. Aarti Drugs Limited is dedicated to improving healthcare through its diverse product range and contract manufacturing services, headquartered in Mumbai, India.

Products and Services

  • APIs: Aarti Drugs provides an extensive range of Active Pharmaceutical Ingredients catering to various therapeutic areas like anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment among others. These APIs are crucial for the development and manufacture of effective medicinal products.
  • Pharmaceutical Intermediates: This includes a range of intermediate products such as tinidazole, celecoxib, ciprofloxacin, clopidogrel, and more. These intermediates are essential components in the synthesis of complex APIs and formulations, showcasing Aarti Drugs’ capability in supporting diverse pharmaceutical manufacturing needs.
  • Specialty Chemicals: The company offers a variety of specialty chemical products like benzene sulphonyl chloride, sodium benzene sulfinate, and calcium fluoride, among others. These products find application across different sectors, including pharmaceuticals, demonstrating the company’s versatility in chemical manufacturing.
  • Development Products: Aarti Drugs is also engaged in the development of new products such as Itraconazole and Fluconazole for antifungal applications; Dabigatran as an anticoagulant; Ticagrelor for cardiovascular diseases; Sitagliptin for antidiabetics; and Alpha Lipoic Acid for antioxidants. This reflects the company's commitment to expanding its portfolio and contributing to advancements in healthcare.
  • Contract Manufacturing Services: In addition to its core offerings, Aarti Drugs provides contract manufacturing services, enabling other pharmaceutical companies to leverage its manufacturing capabilities for their products. This service extends Aarti Drugs' reach beyond its own product line, positioning it as a key player in the pharmaceutical manufacturing industry.
  • Dermatology Products: The company develops products to treat various dermatological conditions, including dermatitis, psoriasis, acne, and eczema. This diversification into dermatology underscores Aarti Drugs’ commitment to addressing a wide spectrum of medical conditions, enhancing overall healthcare outcomes.

Contact Information

Address: Mahendra Industrial Estate
Phone: 91 22 2401 9025